The biological clock targeted at patients can effectively fight liver cancer

Share This Post

According to a preclinical study by scientists at the University of Texas Health Science Center (UTHealth) in Houston, the circadian body clock plays an important role in fighting liver cancer. The result was recently published in the journal Nature Communications.

The circadian clock is an internal 24-hour timekeeping system that can operate in all cells of the body to regulate sleep, metabolism and other important body functions. Dr. Kristin Eckel-Mahan, a senior author of the study and an assistant professor at the Center for Metabolism and Degenerative Diseases, said, “By manipulating the circadian clock, the growth of liver cancer can be suppressed in a mouse model.”

The researchers confirmed their findings in human tissue samples, and Eckel-Mahan ’s team discovered a dysfunctional protein that inhibits the expression of key circadian rhythm transcription factors and blocks tumor suppressors from performing their actions The ability to function normally for 24 hours. When researchers force tumor cells to re-express the lack of circadian protein, tumor cells die. Eckel-Mahan said that 50% of liver tumors express this dysfunctional protein, causing these cells to develop circadian rhythm dysfunction.

These results indicate that the circadian clock targeting patients with HCC may be a promising treatment for the growth and progression of HCC tumors. The next step is to determine how to prevent the interruption of the circadian clock, and study the pharmacological methods known to improve the function of the circadian clock Can stop the growth of these liver tumors.

http://www.sleepreviewmag.com/2018/11/body-clock-liver-cancer-growth/

 

For details on best options for liver cancer treatment, do call us at +91 96 1588 1588 or write to cancerfax@gmail.com.

Spread the love

Subscribe To Our Newsletter

Get updates and never miss a blog from Cancerfax

More To Explore

Development of CAR T Cell therapy in Korea
Cancer treatment in South Korea

Companies in Korea takes a step closer in developing home grown CAR T-Cell therapy

Due to high costs, treatments developed by multinational pharmaceutical corporations are difficult for Korean patients to access. As a result, Korean businesses have created and localised CAR-T treatments in an effort to address these issues. Many businesses have either begun developing CAR-T therapies or declared their intention to do so, including Curocell, Abclon, GC Cell, Ticaros, Helixmith, Toolgen, Cllengene, Eutilex, and Vaxcell Bio.

Spread the love
Polatuzumab
Blood cancer

Polatuzumab vedotin-piiq is approved by USFDA for previously untreated diffuse large B-cell lymphoma, not otherwise specified, and high-grade B-cell lymphoma

For adult patients with high-grade B-cell lymphoma (HGBL), not otherwise specified (NOS), or diffuse large B-cell lymphoma (DLBCL) who have not previously received treatment and who have an International Prognostic Index (IPI) score of 2 or higher, the Food and Drug Administration has approved polatuzumab vedotin-piiq (Polivy, Genentech, Inc.).

Spread the love

Need help? Our team is ready to assist you.

We wish a speedy recovery of your dear and near one.

درمان سرطان در تركيه

Enquiry Form

https://cancerfax.com/